Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.

ABSTRACT:

Background

Following the demonstration that histone deacetylase inhibitors enhanced experimental radiation-induced clonogenic suppression, the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study, combining fractionated radiotherapy with daily vorinostat for pelvic carcinoma, was designed to evaluate both clinical and novel biomarker endpoints, the latter relating to pharmacodynamic indicators of vorinostat action in clinical radiotherapy.

Patients and methods

Potential biomarkers of vorinostat radiosensitizing action, not simultaneously manifesting molecular perturbations elicited by the radiation itself, were explored by gene expression array analysis of study patients' peripheral blood mononuclear cells (PBMC), sampled at baseline (T0) and on-treatment two and 24 hours (

SUBMITTER: Ree AH 

PROVIDER: S-EPMC3934935 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature